Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Bunjes

Showing results (81-90 of 101) with videos related to

Pageof 11
Sort By:
Journal of Cellular and Molecular Medicine|January 16, 2008
Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signallingJ Chen, A Schmitt, B Chen, et al.
Bone Marrow Transplantation|August 5, 2000
CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cellsG Hale, P Jacobs, L Wood, et al.
Lancet (London, England)|May 3, 2000
Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow TransplantationF Frassoni, M Labopin, R Powles, et al.
Blood|July 27, 2001
Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II studyD Bunjes, I Buchmann, C Duncker, et al.
Blood|May 29, 2000
Risk assessment in patients with Ph+ chronic myelogenous leukemia at first relapse after allogeneic stem cell transplant: an EBMT retrospective analysis. The Chronic Leukemia Working Party of the European Group for Blood and Marrow TransplantationC Guglielmi, W Arcese, J Hermans, et al.
Leukemia|February 23, 2011
Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemiaC Craddock, M Labopin, S Pillai, et al.
Bone Marrow Transplantation|March 8, 2016
Strong impact of extramedullary involvement in high-risk AML patients with active disease receiving the FLAMSA conditioning regimen for HSCTS Bohl, S von Harsdorf, M Mulaw, et al.
Bone Marrow Transplantation|November 14, 2017
Reduced-toxicity conditioning for allogeneic hematopoietic cell transplantation in elderly or comorbid patients with AML using fludarabine, BCNU and melphalan: disease stage at transplant determines outcomeV Wais, L Kündgen, S R Bohl, et al.
Leukemia|December 27, 2016
IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM)J Krönke, F Kuchenbauer, M Kull, et al.
Bone Marrow Transplantation|February 9, 2016
Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomasF Heinzelmann, W Bethge, D W Beelen, et al.
Pageof 11

Showing results (81-90 of 101) with videos related to

Sort By:
Pageof 11
Journal of Cellular and Molecular Medicine|January 16, 2008
Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signallingJ Chen, A Schmitt, B Chen, et al.
Bone Marrow Transplantation|August 5, 2000
CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cellsG Hale, P Jacobs, L Wood, et al.
Lancet (London, England)|May 3, 2000
Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow TransplantationF Frassoni, M Labopin, R Powles, et al.
Blood|July 27, 2001
Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II studyD Bunjes, I Buchmann, C Duncker, et al.
Blood|May 29, 2000
Risk assessment in patients with Ph+ chronic myelogenous leukemia at first relapse after allogeneic stem cell transplant: an EBMT retrospective analysis. The Chronic Leukemia Working Party of the European Group for Blood and Marrow TransplantationC Guglielmi, W Arcese, J Hermans, et al.
Leukemia|February 23, 2011
Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemiaC Craddock, M Labopin, S Pillai, et al.
Bone Marrow Transplantation|March 8, 2016
Strong impact of extramedullary involvement in high-risk AML patients with active disease receiving the FLAMSA conditioning regimen for HSCTS Bohl, S von Harsdorf, M Mulaw, et al.
Bone Marrow Transplantation|November 14, 2017
Reduced-toxicity conditioning for allogeneic hematopoietic cell transplantation in elderly or comorbid patients with AML using fludarabine, BCNU and melphalan: disease stage at transplant determines outcomeV Wais, L Kündgen, S R Bohl, et al.
Leukemia|December 27, 2016
IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM)J Krönke, F Kuchenbauer, M Kull, et al.
Bone Marrow Transplantation|February 9, 2016
Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomasF Heinzelmann, W Bethge, D W Beelen, et al.
Pageof 11